{"id":"NCT00974363","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612","officialTitle":"Persistence of Antibodies After Vaccination With GSK Biologicals' Meningococcal Vaccine GSK134612 in Adolescents and Young Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2009-09-10","resultsPosted":"2017-04-12","lastUpdate":"2017-04-12"},"enrollment":697,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"PROCEDURE","name":"Blood Sampling","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"ACTIVE_COMPARATOR"}],"summary":"Subjects were previously vaccinated at 11 to 17 years of age. This extension phase starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension phase. No new subjects will be enrolled.","primaryOutcome":{"measure":"Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups","timeFrame":"At Month 24 post primary dose","effectByArm":[{"arm":"Nimenrix™ Group","deltaMin":404,"sd":null},{"arm":"Mencevax™ Group","deltaMin":132,"sd":null}],"pValues":[]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":5,"countries":["India","Philippines"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":521},"commonTop":[]}}